Abstract:In the present study a clonal Jurkat cell line deficient in expression of Bak was used to analyze the role of Bak in cytochrome c release from mitochondria. The Bak-deficient T leukemic cells were resistant to apoptosis induced by UV, staurosporin, VP-16, bleomycin, or cisplatin. In contrast to wild type Jurkat cells, these Bak-deficient cells did not respond to UV or treatment with these anticancer drugs by membranous phosphatidylserine exposure, DNA breaks, activation of caspases, or release of mitochondrial cytochrome c. The block in the apoptotic cascade was in the mitochondrial mechanism for cytochrome c release because purified mitochondria from Bak-deficient cells failed to release cytochrome c or apoptosis-inducing factor in response to recombinant Bax or truncated Bid. The resistance of Bak-deficient cells to VP-16 was reversed by transduction of the Bak gene into these cells. Also, the cytochrome c releasing capability of the Bak-deficient mitochondria was restored by insertion of recombinant Bak protein into purified mitochondria. Following mitochondrial localization, low dose recombinant Bak restored the mitochondrial release of cytochrome c in response to Bax; at increased doses it induced cytochrome c release itself. The function of Bak is independent of Bid and Bax because recombinant Bak induced cytochrome c release from mitochondria purified from Bax(-/-), Bid(-/-), or Bid(-/-) Bax(-/-) mice. Together, our findings suggest that Bak plays a key role in the apoptotic machinery of cytochrome c release and thus in the chemoresistance of human T leukemic cells.

Survivin inhibits apoptosis in cytotrophoblasts.

Parkin-mediated Ubiquitination Inhibits BAK Apoptotic Activity by Blocking Its Canonical Hydrophobic Groove

Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane

Stepwise activation of the pro-apoptotic protein Bid at mitochondrial membranes

Acetyl-Coenzyme A acyltransferase 2 attenuates the apoptotic effects of BNIP3 in two human cell lines.

Inhibition of BAK-mediated apoptosis by the BH3-only protein BNIP5

Structural basis for proapoptotic activation of Bak by the noncanonical BH3-only protein Pxt1

Crystal structure of Bak bound to the BH3 domain of Bnip5, a noncanonical BH3 domain‐containing protein

Contribution of BH3-domain and Transmembrane-domain to the Activity and Interaction of the Pore-forming Bcl-2 Proteins Bok, Bak, and Bax

The third model of Bax/Bak activation: a Bcl-2 family feud finally resolved?

Apoptotic mitochondrial poration by a growing list of pore‐forming BCL‐2 family proteins

Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins

BNIP3 Heterodimerizes with Bcl-2/Bcl-XL and Induces Cell Death Independent of a Bcl-2 Homology 3 (BH3) Domain at Both Mitochondrial and Nonmitochondrial Sites

Key residues in the VDAC2-BAK complex can be targeted to modulate apoptosis

Bax assembles into large ring‐like structures remodeling the mitochondrial outer membrane in apoptosis

Endogenous BAX and BAK form mosaic rings of variable size and composition on apoptotic mitochondria

BCL‐2‐family protein tBID can act as a BAX‐like effector of apoptosis

Bax, Bak and beyond — mitochondrial performance in apoptosis

A Role For Mitochondrial Bak In Apoptotic Response To Anticancer Drugs

Cyclic-AMP-dependent protein kinase A regulates apoptosis by stabilizing the BH3-only protein Bim.

Molecular and topological reorganizations in mitochondrial architecture interplay during Bax-mediated steps of apoptosis